Skip to main content
VCbacked
Log inGet Started

Mediar Therapeutics

Cambridge, United States

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

$85.0M raised
Mar 2023
Series A
BiotechnologyHealth CareMedicalTherapeutics

Top Investors

Bristol-Myers SquibbSofinnova PartnersMission BioCapitalPureos BioventuresNovartis Venture Fund

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Mediar Therapeutics

How much funding has Mediar Therapeutics raised?
Mediar Therapeutics has raised $85.0M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Who are Mediar Therapeutics's investors?
Mediar Therapeutics's investors include Bristol-Myers Squibb, Sofinnova Partners, Mission BioCapital, Pureos Bioventures, Novartis Venture Fund.
Where is Mediar Therapeutics headquartered?
Mediar Therapeutics is headquartered in Cambridge, United States.
What does Mediar Therapeutics do?
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
What stage is Mediar Therapeutics at?
Mediar Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Mediar Therapeutics — Funding & Investors." VCBacked, March 15, 2023, https://www.vcbacked.co/company/mediar-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2023). Mediar Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/mediar-therapeutics
Wikipedia (cite web)
{{cite web |title=Mediar Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mediar-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong